Non Invasive Prenatal Testing Market: Asia Pacific Is Expected To Exhibit The Fastest Growth Over The Forecast Period

 Non Invasive Prenatal Testing Industry Overview

The global non invasive prenatal testing market size is expected to reach USD 7.71 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.61% from 2022 to 2030. Increasing incidence of chromosomal abnormalities is expected to accelerate market growth. Of all the countries, there is a substantial opportunity in China for non-invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue. Thus, this high incidence rate is anticipated to boost the demand for prenatal tests.

With lockdowns due to COVID-19, NIPT gained attention because it delivers high accuracy screening with minimum risk of infection compared to invasive procedures like chorionic villus sampling and amniocentesis, both of which may necessitate hospitalization and put patients and medical professionals at risk of contracting COVID-19 infection. Moreover, there was increased demand for prescription of NIPTs; however, it was limited to a smaller number of eligible people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario pertaining to non invasive prenatal testing is highly variable. However, the support from the government and favorable insurance policies boost market growth. For instance, in the Netherlands, prenatal testing expenses are fully reimbursed in the second trimester, leading to increased adoption of these tests. Increase in government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China is anticipated to boost the demand for noninvasive prenatal testing solutions and services.

Key players in the market are focusing on new product development to strengthen their product portfolios and offer innovative products to customers. In March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetic laboratories. The probes on the cyto microarrays offer high-resolution detection of copy number variation and copy-neutral loss of heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.


Non Invasive Prenatal Testing Market Segmentation

Grand View Research has segmented the global non invasive prenatal testing market on the basis of gestation period, pregnancy risk, method, technology, product, application, end-use, and region:

Based on the Gestation Period Insights, the market is segmented into 0-12 Weeks, 13-24 Weeks, and 25-36 Weeks.

  • The 13-24 weeks segment held the largest share of over 35.0% in 2021 owing to the maximum number of tests being carried out during this phase of pregnancy. Complementary application of ultrasound with alpha-fetoprotein screening and non-invasive prenatal testing after 12 weeks of pregnancy is expected to fuel the growth of this segment.

 

  • The 0 to 12 weeks gestation period segment accounted for a considerable revenue share in 2021 owing to the availability of a large number of products in the market.

 

Based on the Pregnancy Risk Insights, the market is segmented into High & Average Risk, and Low Risk.

  • The high and average risk segment accounted for the largest revenue share of over 75.0% in 2021. This can be attributed to the growing adoption of these tests in high-risk cases and pregnancies in women 35 years and above.
  • The low-risk segment is expected to register the fastest CAGR from 2022 to 2030. Support from the government, such as budget assignment for average-risk pregnancies, is expected to be a favorable factor for growth.

 

Based on the Method Insights, the market is segmented into Ultrasound Detection, Biochemical Screening Tests, and Cell-free DNA in Maternal Plasma Tests.

  • The cell-free DNA in maternal plasma tests segment accounted for the largest revenue share of over 40.0% in 2021. It is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses.

 

  • Ultrasound detection is deployed as complementary to the Cell-free DNA-based NIPT test, resulting in a lower share of this segment. However, recent advancements in technology and 3D-4D imaging have improved real-time monitoring, safety, and efficiency of the test, which is further expected to propel the segment growth.

 

Based on the Technology Insights, the market is segmented into NGS, Array Technology, PCR, and Others.

  • Next-generation Sequencing (NGS) accounted for the largest revenue share of over 25.0% in 2021. It has gained immense popularity in NIPT. It is commonly used for the identification of trisomy conditions, micro-deletions, and aneuploidies in chromosomes.

 

  • The adoption of Polymerase Chain Reaction (PCR) for NIPT has increased with the commercial launch of Eurofins LifeCodexx-one of the world's first quantitative real-time PCR NIPT assays to detect fetal trisomy 21 (qNIPT).

 

Based on the Product Insights, the market is segmented into Consumables & Reagents, and Instruments.

  • The consumables and reagents segment dominated the market with a share of over 70.0% in 2021 owing to the presence of major players offering a wide range of consumables and reagents for NIPT.

 

  • The instruments segment is expected to grow at a lucrative rate over the forecast period owing to continuous efforts undertaken by instrument manufacturers to develop advanced platforms. PerkinElmer, Inc.

 

Based on the Application Insights, the market is segmented into Trisomy, Microdeletion Syndrome, and Other Applications.

  • Trisomy led the market with a share of over 45.0% in 2021 owing to the rising incidence of chromosomal abnormalities. India has a heavy burden of genetic diseases.

 

  • Technological advancements have expanded the range of testing to whole genome sequencing, and they can detect many additional chromosomal anomalies, such as microdeletions and sex chromosomal abnormalities.

 

Based on the End-use Insights, the market is segmented into Hospitals & Clinics, and Diagnostic Laboratories.

  • Diagnostic laboratories held the largest revenue share of over 60.0% in 2021 owing to the presence of a large number of diagnostic laboratories that offer NIPT across the globe.

 

  • The presence of public and private hospitals that offer NIPT across the globe is fueling the growth of the hospitals and clinics segment. In addition, the rise in research studies in hospitals is expected to increase testing rates in hospital settings.

 

Non Invasive Prenatal Testing Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

This market is consolidated due to the broad range of product offerings and strong distribution network of key entities in emerging and developed countries. In addition, companies are undertaking several strategic initiatives, including partnerships, mergers, acquisitions, and product expansions, to strengthen their market position. For instance, in June 2021, Next-Generation Genomic Co., Ltd. and Illumina, Inc. launched VeriSeq NIPT Solution v2 in Thailand. VeriSeq NIPT Solution offers accurate, reliable, scalable, and fast end-to-end genome-wide noninvasive prenatal testing. Some prominent players in the global non invasive prenatal testing market include:

  • Genesis Genetics (CooperSurgical, Inc.)
  • Natera, Inc.
  • Centogene N.V.
  • Illumina, Inc. (Verinata Health, Inc.)
  • Eurofins LifeCodexx GmbH
  • MedGenome Labs Ltd.
  • Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
  • Myriad Women’s Health, Inc. (Counsyl, Inc.)
  • Progenity, Inc.
  • Qiagen
  • Laboratory Corp. of America Holdings
  • Quest Diagnostics, Inc.

 

Order a free sample PDF of the Non Invasive Prenatal Testing Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

Comments

Post a Comment

Popular posts from this blog

Dna-Based Skin Care Products Market: Offline Distribution Channel Led And Held A Revenue Share

  DNA-based Skin Care Products Industry Overview The global  DNA-based skin care products market  size is expected to reach USD 9.87 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.6% from 2021 to 2028. Consumer awareness of the dangers of using skincare products containing synthetic chemicals is pushing the demand for natural and organic products. Many DNA-based companies have been promoting awareness of DNA-based skincare products through digital and social media campaigns because today's consumers are tech-savvy and want products that are best suited to them.   Everyone's skin is different, so instead of a generic approach from over-the-counter items, consumers need a regimen that is tailored to their own needs. Consumers are now being targeted more directly by skincare specialists, who are prescribing a customized range of products. The Skin360 Face Scanner app from Neutrogena identifies over two...
Read more

Circulating Tumor Cells Market Players: BIOCEPT, Inc., Biocep Ltd., Ikonisys Inc., And Miltenyi Biotec

  Circulating Tumor Cells Industry Overview The global  circulating tumor cells market  size is expected to reach USD 18.3 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.7% from 2021 to 2027. Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.   Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex...
Read more

Flow Cytometry Market: Asia Pacific Is Projected To Exhibit Exponential Growth During The Forecast Period

  Flow Cytometry Industry Overview The global  flow cytometry market  size is expected to reach a value of USD 11.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.9% from 2021 to 2027. The high prevalence of chronic diseases, the introduction of technologically advanced flow cytometry solutions, and increasing R&D investments in the pharmaceutical industry are expected to propel market growth over the forecast period.   Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. Also, in January 2019, Beckman Coulter, a subsidiary of Danaher Corporation, expanded its clinical flow cytometry portfolio with the launch of its new ClearLLab 10C System. This newly la...
Read more